FDA plans ultra-fast review of three psychedelic drugs following Trump directive

The Food and Drug Administration (FDA) is fast-tracking the review of three psychedelic drugs for mental health treatment, including depression and PTSD. This move follows President Trump’s executive order to speed up research on psychedelics, which are currently illegal under federal law. The FDA has given priority review vouchers to companies studying psilocybin, found in magic mushrooms, and methylone, related to MDMA. These vouchers aim to shorten the review process but do not guarantee approval. The initiative reflects growing support for psychedelics among Trump supporters, including veterans. The FDA also approved initial testing of a drug related to ibogaine for alcohol use disorder, despite its potential risks. This decision may renew scrutiny of the FDA’s fast-track program, which some believe favors politically connected companies. QUESTION: How might the fast-tracking of psychedelic drugs for mental health treatment impact the future of mental health care?